** Shares of medical device maker ResMed RMD.N fall 3.8% to $244.56
** RMD's rival Apnimed said late on Monday that its oral pill met the main goal in a late-stage study to treat obstructive sleep apnea
** Apnimed's experimental drug, AD109, showed a mean reduction of 55.1% on a scale that measures mild, moderate and severe obstructive sleep apnea
** Apnimed says the drug significantly improved oxygenation and reduced disease severity in patients
** It plans to submit a marketing application to the U.S. FDA for the drug, AD109, by early 2026
** ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive treatment option for sleep apnea characterized by brief interruptions of breathing during sleep
** Including session's moves, RMD up 10.8% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。